Check out our list of top companies

Check out our carefully compiled lists of the most relevant and impactful companies within their fields.

Best 7 Multi-CDN Providers in 2026

Multi-CDN has moved from backup plan to core delivery architecture. This guide ranks the 7 best Multi-CDN providers of 2026, led by IO River, and breaks down steering, behavioral consistency, observability, and governance factors that determine real resilience.
The team of Treeview, one of the leading AR and VR comapnies, wearing virtual reality glasses

25 VR and Augmented Reality Development Companies in 2026

Explore the top 25 best virtual reality (VR) and augmented reality (AR) development companies in the world

The Best Virtual and Augmented Reality Gaming Companies in 2026

Immersive gaming is thriving in 2025, and the most exciting players aren’t just the biggest names. From enterprise-focused XR pioneers like Treeview to story-driven hits by Polyarc and the indie innovation of Fast Travel Games, these 15 standout VR/AR studios prove that the future of gaming is both deeply personal and wildly creative.

Best 5 Israeli VCs Active in MedTech and Digital Health

Compare the best tech marketing agencies in 2026 for PR, SEO, ABM, and demand generation. Find the right fit for your SaaS or B2B tech brand.
Top Sustainable Packaging Companies 2026

Top Sustainable Packaging Companies 2026

Find the best sustainable packaging companies of 2026. From seaweed to molded fiber, compare materials, formats, and what actually works.
Top Defense Tech Startups Building the Next Generation of Military Technology

Top Defense Tech Startups Building the Next Generation of Military Technology

Anduril, Saronic, Helsing, and more: a close look at the defense tech startups building the next generation of military technology.
Best Tech Marketing Agencies in 2026

Best Tech Marketing Agencies in 2026

Compare the best tech marketing agencies in 2026 for PR, SEO, ABM, and demand generation. Find the right fit for your SaaS or B2B tech brand.
Read full story

Check out our list of top unicorns

Read and learn about the biggest companies that various countries have produced, how they made it, and what the future looks like for them.
16 Robotics Unicorns in 2026

16 Robotics Unicorns in 2026

Meet the 16 private robotics companies valued at $1B+ in 2026, from humanoid robots to defense autonomy and warehouse systems.
Healthtech Unicorns to Consider in 2026

Healthtech Unicorns to Consider in 2026

The healthtech unicorns worth watching in 2026 are tied to real care needs. Here are the private companies investors still take seriously.
10 Biotech Unicorn Startups to Watch in 2026

10 Biotech Unicorn Startups to Watch in 2026

Meet the private biotech companies valued at $1 billion or more in 2026 and find out what still makes them worth watching.
10 Insurtech Unicorn Companies to Watch in 2026

10 Insurtech Unicorn Companies to Watch in 2026

Discover the 10 insurtech unicorn companies shaping private insurance in 2026, from cyber specialists to embedded platforms.
14 Edtech Unicorns to Consider in 2026

14 Edtech Unicorns to Consider in 2026

Which edtech companies are still worth watching in 2026? We break down 14 private unicorns across training, language, and career tech.
Fintech Unicorns Around the World to Watch in 2026

Fintech Unicorns Around the World to Watch in 2026

Stripe, Revolut, Klarna, Ramp, and more. A clear look at the private fintech unicorns still worth watching in 2026.
Cybersecurity Unicorns Around the World to Watch in 2026

Cybersecurity Unicorns Around the World to Watch in 2026

The top private cybersecurity companies worth watching in 2026, from data security to supply chain protection. Valuations, funding, and what they actually do.
Read full story

Explore our collection of top interviews

Dive into our thoughtfully curated selection of insightful and impactful interviews with leaders and innovators in their fields.
Maisa CEO David Villalón

AI Costs Aren't the Problem. Enterprise AI Architecture Is, Says Maisa CEO David Villalón

Maisa CEO David Villalón explains why enterprise AI costs stem from poor architecture, not model pricing, and how multi-model systems fix it.
Carl Livie is Co-Founder and Chief Executive Officer of JustPlay

Inside JustPlay’s Vision for the Next Generation of Reward Ecosystems

JustPlay CEO Carl Livie explains how rewarded gaming can create sustainable value for players through a fully integrated ecosystem.
Encube

Interview with Hugo Nordell, CEO of Encube: Rethinking hardware manufacturing workflows

Hugo Nordell of Encube on why AI-powered hardware development tools are now essential for European manufacturers facing talent gaps and supply chain shifts.
Communities, Not Studios: Victor Folmann on Gaming’s New Power Players

Communities, Not Studios: Victor Folmann on Gaming’s New Power Players

Victor Folmann on why gaming communities, not studios, will shape the next generation of games and how Chosen is betting on that.
Interview: Zakhar Azatian, CEO & Founder, BeHard

Interview: Zakhar Azatian, CEO & Founder, BeHard

Zakhar Azatian built BeHard to 1M users and $490K MRR with no outside funding. Here's the growth system behind it.
Will Weise

A Breakthrough Bongo Antelope Birth Shows How Reproductive Technology Could Help Stop Extinction

Critically endangered Bongo antelope born to Eland surrogate in Texas breakthrough. Dr. Will Weise explains how reproductive tech fights extinction.

Shaping Fintech’s Next Chapter: An Interview with Oleg Seitov, Head of Finance at xpate

xpate's Head of Finance Oleg Seitov shares insights on balancing fintech innovation with discipline, AI automation, and sustainable growth strategies.
Read full story

Discover our top blog articles

Explore our carefully curated selection of engaging and informative blog articles on a variety of topics.
The Best 10 PR Agencies in Europe 2027

The Best 10 PR Agencies in Europe 2027

Discover the 10 best PR agencies in Europe for 2027. Compare their specialties, international reach, services, and proven client results.
Best PR agencies for Series A, B and C SaaS companies

Best PR agencies for Series A, B and C SaaS companies

Explore 12 PR agencies for Series A, B and C SaaS companies. Compare industry expertise, funding campaign experience and media relations services.

Aircraft Management Costs Explained: Crew, Maintenance, Hangar, and Operations

Private aircraft ownership costs go far beyond the purchase price. This guide breaks down crew, maintenance, hangar, fuel, and insurance expenses, and explains how understanding fixed versus variable costs helps owners budget accurately and avoid surprises.

Best Sovereign Cloud Providers in Europe

Compare the 10 best sovereign cloud providers in Europe for 2026, including Ilkari, OVHcloud, Scaleway, IONOS, AWS, Microsoft and more.
Best Sovereign Cloud Providers in Latin America

Best Sovereign Cloud Providers in Latin America

Compare 10 leading sovereign cloud providers in Latin America, including regional, government and global options for regulated workloads.

Three Reasons to Have Digital Signage

Digital signage gives businesses a flexible alternative to printed signs, with content that updates instantly and engages more effectively. This guide covers three reasons to make the switch, from stronger communication and fresher content to a more polished customer experience.

The Best Virtual and Augmented Reality Gaming Companies in 2026

Immersive gaming is thriving in 2025, and the most exciting players aren’t just the biggest names. From enterprise-focused XR pioneers like Treeview to story-driven hits by Polyarc and the indie innovation of Fast Travel Games, these 15 standout VR/AR studios prove that the future of gaming is both deeply personal and wildly creative.
Read full story

UK Biotech NRG Therapeutics Raises $67 million to Tackle ALS and Parkinson's

Key Points
  • NRG Therapeutics raises $67 million Series B led by Dementia Discovery Fund to advance ALS and Parkinson's treatments.
  • Investors include British Business Bank, M Ventures, Novartis Venture Fund, Criteria Bio Ventures, Omega Funds, Brandon Capital.
  • Funding supports clinical proof of concept for NRG5051, targeting mitochondrial dysfunction in neurodegeneration.
September 8, 2025
NRG Therapeutics’ founding team: left to right Richard Rutter (CSO); Neil Miller (CEO); Grant Hawthorn (COO)
Credits: NRG Therapeutics

NRG Therapeutics has successfully closed an oversubscribed $67 million Series B financing round. The UK-based neuroscience company plans to use these funds to advance its novel approach targeting mitochondrial dysfunction in neurodegenerative diseases.

SV Health Investors' Dementia Discovery Fund led the round, bringing together several prominent life science investors. New backers include British Business Bank, M Ventures, Novartis Venture Fund, and Criteria Bio Ventures. Existing investors Omega Funds and Brandon Capital also participated, while founding investor Parkinson's UK continues its support through the Parkinson's Virtual Biotech.

Targeting a Critical Gap in Neurodegeneration Treatment

The funding addresses significant unmet medical needs in neurodegenerative disorders. Parkinson's disease affects millions worldwide, with global prevalence expected to double by 2050. Current treatments only provide temporary symptom relief without slowing disease progression.

ALS, also known as motor neurone disease, presents an even more urgent challenge as a rare but rapidly progressing condition. While the FDA approved Qalsody in 2023 for a specific genetic form of ALS, most patients with the sporadic version still lack effective treatment options.

Advancing Clinical Programs and Drug Development

The Series B proceeds will primarily fund NRG's journey toward clinical proof of concept in ALS/MND using their lead compound, NRG5051. The company also plans to generate meaningful clinical data in Parkinson's patients through a Phase 1b study.

NRG5051 represents a first-in-class oral inhibitor targeting the mitochondrial permeability transition pore (mPTP). The drug has completed IND-enabling studies and is scheduled to enter first-in-human trials in early 2026. Preclinical results show the compound provides significant neuroprotection and reduces neuroinflammation in both Parkinson's and ALS models.

Building on Novel Scientific Insights

Founded as a private neuroscience company, NRG Therapeutics focuses on mitochondrial dysfunction as a key driver of neurodegeneration. The company operates from the Stevenage Bioscience Catalyst in the UK, where it has developed its understanding of mPTP biology.

Co-founder and CEO Neil Miller brings experience in drug development for neurological conditions. Under his leadership, NRG has identified a novel regulator of the mPTP that enables small molecule inhibition. "Developing new drugs to treat neurological diseases is very challenging but is receiving increased interest given the high unmet medical need and growing prevalence in aging populations," Miller explained.

The company's approach targets mitochondria, cellular powerhouses that are particularly important for energy-hungry neurons. In Parkinson's disease, substantia nigra neurons face high energy demands, while motor neurons in ALS show similar vulnerability. Pathological proteins like α-synuclein in Parkinson's and TDP-43 in ALS damage mitochondria, contributing to disease progression.

Strong Investor Confidence in Platform Technology

The investment round reflects growing confidence in NRG's scientific platform and clinical potential. Laurence Barker, Partner leading the Dementia Discovery Fund at SV Health Investors, highlighted the strength of preclinical data supporting NRG's approach.

"The strength and breadth of NRG's pre-clinical data gives us real confidence that NRG's approach could halt or significantly slow disease progression across multiple neurodegenerative diseases," Barker noted. Francesco Draetta from Omega Funds praised the company's progress over three years, particularly in advancing both drug development and scientific understanding of mitochondrial dysfunction.

The funding brings new board members including Laurence Barker, Emma Johnson from British Business Bank, Charlotte Kremers from M Ventures, and Florian Muellershausen from Novartis Venture Fund. Professor David Dexter, Director of Research at Parkinson's UK, joins as a special advisor on Parkinson's programs.

Last related articles

linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram